Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
1.060
+0.020 (1.92%)
Nov 21, 2024, 2:39 PM EST - Market open
Ovid Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 0.63 | 0.39 | 1.5 | 208.38 | 12.62 | - | Upgrade
|
Revenue Growth (YoY) | 113.21% | -73.93% | -99.28% | 1551.57% | - | - | Upgrade
|
Gross Profit | 0.63 | 0.39 | 1.5 | 208.38 | 12.62 | - | Upgrade
|
Selling, General & Admin | 24.8 | 31.09 | 32.43 | 37.23 | 30.63 | 19.25 | Upgrade
|
Research & Development | 41.49 | 28.59 | 24.62 | 46.94 | 63.42 | 42.16 | Upgrade
|
Operating Expenses | 66.28 | 59.67 | 57.05 | 84.17 | 94.05 | 61.41 | Upgrade
|
Operating Income | -65.65 | -59.28 | -55.55 | 124.21 | -81.43 | -61.41 | Upgrade
|
Interest & Investment Income | - | - | - | - | 0.4 | 0.95 | Upgrade
|
Other Non Operating Income (Expenses) | 31.85 | 4.94 | 1.83 | -0.05 | - | - | Upgrade
|
EBT Excluding Unusual Items | -33.8 | -54.34 | -53.71 | 124.16 | -81.04 | -60.46 | Upgrade
|
Gain (Loss) on Sale of Investments | 5 | 2 | -0.45 | - | - | - | Upgrade
|
Pretax Income | -32.5 | -52.34 | -54.17 | 124.16 | -81.04 | -60.46 | Upgrade
|
Income Tax Expense | - | - | - | 1.33 | - | - | Upgrade
|
Net Income | -32.5 | -52.34 | -54.17 | 122.83 | -81.04 | -60.46 | Upgrade
|
Preferred Dividends & Other Adjustments | - | - | - | 3 | - | - | Upgrade
|
Net Income to Common | -32.5 | -52.34 | -54.17 | 119.84 | -81.04 | -60.46 | Upgrade
|
Shares Outstanding (Basic) | 71 | 71 | 70 | 67 | 58 | 39 | Upgrade
|
Shares Outstanding (Diluted) | 71 | 71 | 70 | 68 | 58 | 39 | Upgrade
|
Shares Change (YoY) | 0.42% | 0.22% | 3.46% | 16.45% | 49.04% | 59.22% | Upgrade
|
EPS (Basic) | -0.46 | -0.74 | -0.77 | 1.78 | -1.39 | -1.54 | Upgrade
|
EPS (Diluted) | -0.46 | -0.74 | -0.77 | 1.76 | -1.39 | -1.54 | Upgrade
|
Free Cash Flow | -57.92 | -45.82 | -56.45 | 118.43 | -51.71 | -51.15 | Upgrade
|
Free Cash Flow Per Share | -0.82 | -0.65 | -0.80 | 1.74 | -0.88 | -1.30 | Upgrade
|
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | Upgrade
|
Operating Margin | -10392.91% | -15134.60% | -3696.44% | 59.61% | -645.40% | - | Upgrade
|
Profit Margin | -5145.20% | -13362.17% | -3604.66% | 57.51% | -642.26% | - | Upgrade
|
Free Cash Flow Margin | -9169.18% | -11698.19% | -3756.55% | 56.83% | -409.85% | - | Upgrade
|
EBITDA | -65.06 | -58.71 | -55.04 | 124.45 | -81.12 | -61.15 | Upgrade
|
EBITDA Margin | - | - | - | 59.72% | - | - | Upgrade
|
D&A For EBITDA | 0.59 | 0.57 | 0.51 | 0.24 | 0.31 | 0.26 | Upgrade
|
EBIT | -65.65 | -59.28 | -55.55 | 124.21 | -81.43 | -61.41 | Upgrade
|
EBIT Margin | - | - | - | 59.61% | - | - | Upgrade
|
Effective Tax Rate | - | - | - | 1.07% | - | - | Upgrade
|
Revenue as Reported | 0.63 | 0.39 | 1.5 | 208.38 | 12.62 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.